Literature DB >> 35688941

Perinatal outcomes of two consecutive strategies for the management of fetal growth restriction: a before-after study.

Sabrina Paola Demirdjian1, Cesar Hernan Meller2, Maria Celeste Berruet3, Gonzalo Dosdoglirian3, Adolfo Etchegaray3.   

Abstract

PURPOSE: We aim to compare the perinatal outcomes of two consecutive management strategies for fetal growth restriction (FGR), with or without the inclusion of additional Doppler parameters.
METHODS: A quasi-experimental before/after study was conducted in which we compared a composite perinatal outcome, prematurity rate, and neonatal complications between two management strategies in small fetuses. In the strategy 1 (S1), the management was based on fetal biometry and umbilical artery Doppler. The second strategy (S2) added the assessment of uterine and middle cerebral artery Doppler. We also compared outcomes between strategies according to early (≤ 32 weeks) and late (> 32 weeks) diagnosis subgroups.
RESULTS: We included 396 patients, 163 in S1 and 233 in S2. There were no significant differences in the perinatal composite outcome (p 0.98), prematurity (p 0.19), or in the subgroup analysis. We found a significant reduction in respiratory distress syndrome (RDS) rate with S2 both globally (OR 0.50, p 0.02), and in the early diagnosis subgroup (OR 0.45, p 0.01). In addition, we observed a significant reduction in the incidence of sepsis with S2 both globally (OR 0.30, p 0.04) and in the early diagnosis subgroup (OR 0.25, p 0.02). We did not observe significant differences in necrotizing enterocolitis (p 0.41) and intraventricular hemorrhage (p 1.00).
CONCLUSION: The expanded strategy for the management of FGR did not show significant differences in the primary composite outcome or prematurity. However, it was associated with a lower incidence of RDS and neonatal sepsis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Doppler assessment; Fetal growth restriction; Low birthweight; Neonatal morbidity; Placental insufficiency; Respiratory distress syndrome

Year:  2022        PMID: 35688941     DOI: 10.1007/s00404-022-06641-x

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  24 in total

Review 1.  Adult sequelae of intrauterine growth restriction.

Authors:  Michael G Ross; Marie H Beall
Journal:  Semin Perinatol       Date:  2008-06       Impact factor: 3.300

2.  NHS in England balances books, but local deficits mean worse care in some areas, says report.

Authors:  Nigel Hawkes
Journal:  BMJ       Date:  2018-12-19

Review 3.  Impact of intrauterine growth restriction on long-term health.

Authors:  Rehana A Salam; Jai K Das; Zulfiqar A Bhutta
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2014-05       Impact factor: 4.294

Review 4.  Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.

Authors:  Lesley M McCowan; Francesc Figueras; Ngaire H Anderson
Journal:  Am J Obstet Gynecol       Date:  2018-02       Impact factor: 8.661

5.  Consensus definition of fetal growth restriction: a Delphi procedure.

Authors:  S J Gordijn; I M Beune; B Thilaganathan; A Papageorghiou; A A Baschat; P N Baker; R M Silver; K Wynia; W Ganzevoort
Journal:  Ultrasound Obstet Gynecol       Date:  2016-09       Impact factor: 7.299

Review 6.  A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour.

Authors:  D Villanueva-García; D Mota-Rojas; R Hernández-González; P Sánchez-Aparicio; M Alonso-Spilsbury; M E Trujillo-Ortega; R Ramírez Necoechea; A A Nava-Ocampo
Journal:  J Obstet Gynaecol       Date:  2007-04       Impact factor: 1.246

7.  Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial.

Authors:  Andrew Sharp; Christine Cornforth; Richard Jackson; Jane Harrold; Mark A Turner; Louise C Kenny; Philip N Baker; Edward D Johnstone; Asma Khalil; Peter von Dadelszen; Aris T Papageorghiou; Zarko Alfirevic
Journal:  Lancet Child Adolesc Health       Date:  2017-12-07

8.  EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction.

Authors:  Rebecca Spencer; Gareth Ambler; Jana Brodszki; Anke Diemert; Francesc Figueras; Eduard Gratacós; Stefan R Hansson; Kurt Hecher; Angela Huertas-Ceballos; Neil Marlow; Karel Marsál; Eva Morsing; Donald Peebles; Carlo Rossi; Neil J Sebire; John F Timms; Anna L David
Journal:  BMC Pregnancy Childbirth       Date:  2017-01-23       Impact factor: 3.007

Review 9.  Prevalence of diabetes and obesity in association with prematurity and growth restriction.

Authors:  Gretchen Kopec; Prem S Shekhawat; Maroun J Mhanna
Journal:  Diabetes Metab Syndr Obes       Date:  2017-07-06       Impact factor: 3.168

10.  ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction.

Authors:  C C Lees; T Stampalija; A Baschat; F da Silva Costa; E Ferrazzi; F Figueras; K Hecher; J Kingdom; L C Poon; L J Salomon; J Unterscheider
Journal:  Ultrasound Obstet Gynecol       Date:  2020-08       Impact factor: 7.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.